Novartis Pharmaceuticals Corporation Diovan (valsartan) 160 mg Recall (Jun 2027)
Announced 2026-08-19 · FDA
Diovan (valsartan) 160 mg, 90 tablets (Rx only) is recalled due to failed dissolution specifications. Lot AV5913C with expiry 6/2027 is included in the recall, distributed nationwide in the United States, and the FDA is the agency involved.
| Brand | Novartis Pharmaceuticals Corporation |
|---|---|
| Product | Diovan (valsartan) 160 mg, 90 tablets, Rx only, Manufactured by: Patheon Manufacturing Services LLC, Greenville, NC 27834, Distributed by: Novartis Pharmaceutical Corp, East Hanover, NJ 07936, NDC 0078-0359-34 |
| Reason | Failed Dissolution Specifications |
| Severity | moderate |
| Distribution | US Nationwide |
| Agency | FDA |
| Recall / campaign no. | Lot AV5913C, Expiry: 6/2027 |
WHAT YOU SHOULD DO
- Stop using Lot AV5913C Diovan 160 mg.
- Consult your healthcare provider or pharmacist for guidance and potential replacement.
- Return the recalled product to the place of purchase or follow recall instructions from the FDA.
This is an automatically maintained record of an official recall notice. Details can change; always follow the official notice linked above. See all records in the Recall Database.